Generated Narrative: Composition 236537 version: 78; Last updated: 2025-10-21 14:50:13+0000; Language: en Profile: SummaryOfFindings url: https://fevir.net/resources/Composition/236537 identifier: FEvIR Object Identifier/236537, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-summary-of-findings-85390-85789 status: Final type: Summary of Findings date: 2025-10-21 14:50:13+0000 author: Qiukui Hao title: SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk custodian: Computable Publishing LLC relatesTo type: Part Of target: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) relatesTo type: Part Of target: ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk relatesTo type: Cite As target: SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236537. Revised 2025-10-21. Available at: https://fevir.net/resources/Composition/236537. Computable resource at: https://fevir.net/resources/Composition/236537#json.
SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes
ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236537. Revised 2025-10-21. Available at: https://fevir.net/resources/Composition/236537. Computable resource at: https://fevir.net/resources/Composition/236537#json.
[No narrative text.]
Outcome
Sample Size
Result Without Treatment
Result With Treatment (Observed)
Result with intervention alone (calculated)
result with intervention with calculated value derived from the control group and effect estimate
Result With Treatment (Calculated)
Effect Estimate
Certainty of Evidence
What this means
[No data.]
Summary of findings entry for a single outcome
OutcomeDefinition: All-cause mortality
34 studies, 69035 participants
MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
12%
MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
Moderate certainty -- Due to serious imprecision
GLP-1 receptor agonists probably reduce the risk of death compared with standard care.
OutcomeDefinition: Cardiovascular mortality
20 studies, 63455 participants
MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
7.9%
MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
GLP-1 receptor agonists probably reduce the risk of cardiovascular death compared with standard care.
OutcomeDefinition: Nonfatal myocardial infarction
32 studies, 67956 participants
MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
10%
MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
GLP-1 receptor agonists probably reduce the risk of nonfatal myocardial infarction compared with standard care.
OutcomeDefinition: Nonfatal stroke
29 studies, 66900 participants
MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
9.2%
MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
GLP-1 receptor agonists probably reduce the risk of nonfatal stroke compared with standard care.
OutcomeDefinition: End-stage kidney disease
4 studies, 10762 participants
MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
1.6%
MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
High certainty
There is no important difference between GLP-1 receptor agonists and standard care.
OutcomeDefinition: Heart failure
13 studies, 46696 participants
MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
7.6%
MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
GLP-1 receptor agonists probably reduce the risk of heart failure compared with standard care.
OutcomeDefinition: Serious hyperglycaemia
12 studies, 30066 participants
MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
2.5%
MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
GLP-1 receptor agonists reduce the risk of serious hyperglycaemia compared with standard care.
OutcomeDefinition: Severe gastrointestinal events
7 studies, 24638 participants
MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
4.4%
MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
Low certainty -- Due to inconsistency and serious imprecision.
GLP-1 receptor agonists may increase the risk of severe gastrointestinal events compared with standard care.
OutcomeDefinition: Health-related quality of life
[No sample size data.]
MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
[Not a proportion.]
MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
[Not a difference in proportions.]
Low certainty -- Due to very serious imprecision
GLP-1 receptor agonists may have little or no impact on health-related quality of life.
OutcomeDefinition: Body weight
60 studies, 44432 participants
MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
Low certainty -- Due to very serious inconsistency
GLP-1 receptor agonists may reduce body weight compared with standard care.